These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 38843331)

  • 1. Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.
    Klomp JA; Klomp JE; Stalnecker CA; Bryant KL; Edwards AC; Drizyte-Miller K; Hibshman PS; Diehl JN; Lee YS; Morales AJ; Taylor KE; Peng S; Tran NL; Herring LE; Prevatte AW; Barker NK; Hover LD; Hallin J; Sorokin A; Kanikarla PM; Chowdhury S; Coker O; Lee HM; Goodwin CM; Gautam P; Olson P; Christensen JG; Shen JP; Kopetz S; Graves LM; Lim KH; Wang-Gillam A; Wennerberg K; Cox AD; Der CJ
    Science; 2024 Jun; 384(6700):eadk0775. PubMed ID: 38843331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer.
    Sun Y; Peng W; He W; Luo M; Chang G; Shen J; Zhao X; Hu Y
    J Exp Clin Cancer Res; 2018 Jul; 37(1):166. PubMed ID: 30041673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer.
    Diehl JN; Hibshman PS; Ozkan-Dagliyan I; Goodwin CM; Howard SV; Cox AD; Der CJ
    Adv Cancer Res; 2022; 153():101-130. PubMed ID: 35101228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer.
    Klomp JE; Diehl JN; Klomp JA; Edwards AC; Yang R; Morales AJ; Taylor KE; Drizyte-Miller K; Bryant KL; Schaefer A; Johnson JL; Huntsman EM; Yaron TM; Pierobon M; Baldelli E; Prevatte AW; Barker NK; Herring LE; Petricoin EF; Graves LM; Cantley LC; Cox AD; Der CJ; Stalnecker CA
    Science; 2024 Jun; 384(6700):eadk0850. PubMed ID: 38843329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer.
    Diehl JN; Klomp JE; Snare KR; Hibshman PS; Blake DR; Kaiser ZD; Gilbert TSK; Baldelli E; Pierobon M; Papke B; Yang R; Hodge RG; Rashid NU; Petricoin EF; Herring LE; Graves LM; Cox AD; Der CJ
    J Biol Chem; 2021 Nov; 297(5):101335. PubMed ID: 34688654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.
    Ozkan-Dagliyan I; Diehl JN; George SD; Schaefer A; Papke B; Klotz-Noack K; Waters AM; Goodwin CM; Gautam P; Pierobon M; Peng S; Gilbert TSK; Lin KH; Dagliyan O; Wennerberg K; Petricoin EF; Tran NL; Bhagwat SV; Tiu RV; Peng SB; Herring LE; Graves LM; Sers C; Wood KC; Cox AD; Der CJ
    Cell Rep; 2020 Jun; 31(11):107764. PubMed ID: 32553168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
    Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
    Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical KRAS
    Hobbs GA; Baker NM; Miermont AM; Thurman RD; Pierobon M; Tran TH; Anderson AO; Waters AM; Diehl JN; Papke B; Hodge RG; Klomp JE; Goodwin CM; DeLiberty JM; Wang J; Ng RWS; Gautam P; Bryant KL; Esposito D; Campbell SL; Petricoin EF; Simanshu DK; Aguirre AJ; Wolpin BM; Wennerberg K; Rudloff U; Cox AD; Der CJ
    Cancer Discov; 2020 Jan; 10(1):104-123. PubMed ID: 31649109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia.
    Shi G; DiRenzo D; Qu C; Barney D; Miley D; Konieczny SF
    Oncogene; 2013 Apr; 32(15):1950-8. PubMed ID: 22665051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives.
    Adamopoulos C; Cave DD; Papavassiliou AG
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer.
    Yang K; Li Y; Lian G; Lin H; Shang C; Zeng L; Chen S; Li J; Huang C; Huang K; Chen Y
    Int J Cancer; 2018 Jun; 142(11):2323-2334. PubMed ID: 29315556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells.
    Khandakar GI; Satoh R; Takasaki T; Fujitani K; Tanabe G; Sakai K; Nishio K; Sugiura R
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
    Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
    Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.
    Xie F; Li C; Zhang X; Peng W; Wen T
    Biomed Pharmacother; 2019 Nov; 119():109424. PubMed ID: 31521891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The protein kinase MAP3K19 phosphorylates MAP2Ks and thereby activates ERK and JNK kinases and increases viability of KRAS-mutant lung cancer cells.
    Hoang VT; Nyswaner K; Torres-Ayuso P; Brognard J
    J Biol Chem; 2020 Jun; 295(25):8470-8479. PubMed ID: 32358059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGF receptor is required for KRAS-induced pancreatic tumorigenesis.
    Ardito CM; Grüner BM; Takeuchi KK; Lubeseder-Martellato C; Teichmann N; Mazur PK; Delgiorno KE; Carpenter ES; Halbrook CJ; Hall JC; Pal D; Briel T; Herner A; Trajkovic-Arsic M; Sipos B; Liou GY; Storz P; Murray NR; Threadgill DW; Sibilia M; Washington MK; Wilson CL; Schmid RM; Raines EW; Crawford HC; Siveke JT
    Cancer Cell; 2012 Sep; 22(3):304-17. PubMed ID: 22975374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
    Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
    Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma.
    Ju HQ; Ying H; Tian T; Ling J; Fu J; Lu Y; Wu M; Yang L; Achreja A; Chen G; Zhuang Z; Wang H; Nagrath D; Yao J; Hung MC; DePinho RA; Huang P; Xu RH; Chiao PJ
    Nat Commun; 2017 Feb; 8():14437. PubMed ID: 28232723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.